The rapid technological developments in diagnostics and innovations in multimodal therapy in the field of hematology and medical oncology were the focus of the annual conference. While immunotherapies with monoclonal tumor-specific antibodies and checkpoint inhibitors already dominate everyday oncological practice, immunotherapeutic combination approaches and cell therapy-based immunotherapies are the focus of current clinical trials. These were examined and discussed in more detail.
This content is machine-translated. Please contact us if you need professional translation services.
- InFo ONKOLOGIE & HÄMATOLOGIE